CompanyARDXNasdaqFremont, CA

Ardelyx

Ardelyx is a commercial-stage biopharmaceutical company developing NHE3 inhibitors.

SEC EDGAR ClinicalTrials.gov ardelyx.com

424B3Sep 11Latest SEC filing

Aug 6Latest story

August 2026

Ardelyx revises IBSRELA guidance, pulls XPHOZAH long-term outlook amid payor hurdles

Aug 6Quarterly updateArdelyx tenapanor

July 2026

Ardelyx draws $50 million Term F Loan under existing credit agreement

Jul 2FinancingArdelyx